Home
About Us
Product Pipeline
Contact

Dermata

Home
About Us
Product Pipeline
Investors
Contact

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 20, 2023 4:30pm EDT

Dermata Therapeutics Announces Closing of $5.0 Million Public Offering

Mar 16, 2023 1:15pm EDT

Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering

Feb 21, 2023 4:05pm EST

Dermata Therapeutics Provides Corporate Update and Reports Full Year 2022 Financial Results

Dec 05, 2022 8:30am EST

Dermata Announces Topline Results from DMT310 Phase 2 Clinical Trial for the Treatment of Moderate-to-Severe Rosacea

Nov 10, 2022 5:20pm EST

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results

Sep 06, 2022 9:00am EDT

Dermata to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 24, 2022 4:05pm EDT

Dermata to Participate in the Gilmartin Group Emerging Growth Company Showcase

Aug 15, 2022 4:05pm EDT

Dermata Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results

Jun 13, 2022 9:00am EDT

Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea

May 23, 2022 9:00am EDT

Dermata to Present at the H.C. Wainwright Global Investment Conference

  • 1
  • 2
  • 3
  • 4
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Back to Top
Dermata Therapeutics, Inc.info@dermatarx.com